Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Nov 11, 2010

Premium

Alnylam Pharmaceuticals said that it has expanded its management team to include two new vice presidents and a CSO.

Kenneth Koblan, who has been named CSO, previously held various positions within Merck Research Laboratories, most recently vice president and site head of Rahway Basic Research. He holds a PhD in biochemistry from Johns Hopkins University.

Alnylam's previous CSO, John Schmidt, left the company in August of 2009.

The company also said that it has appointed Steven Bossone as its vice president of intellectual property and Garvin Warner as its vice president of preclinical development.

Bossone previously served as senior patent attorney at Shire, and had worked as a scientist in the oncology group of Millennium Pharmaceuticals. Warner previously served as assistant vice president and therapeutic area head in drug safety and metabolism at Genetics Institute/Wyeth.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.